Jane Street Group LLC Has $231,000 Stock Holdings in Omeros Co. (NASDAQ:OMER)

Jane Street Group LLC grew its holdings in Omeros Co. (NASDAQ:OMER) by 15.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,277 shares of the biopharmaceutical company’s stock after buying an additional 8,010 shares during the period. Jane Street Group LLC owned 0.10% of Omeros worth $231,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in OMER. BNP Paribas Financial Markets increased its stake in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. SPC Financial Inc. acquired a new position in shares of Omeros during the 3rd quarter worth $77,000. SG Americas Securities LLC acquired a new position in shares of Omeros during the 3rd quarter worth $80,000. AQR Capital Management LLC acquired a new position in shares of Omeros during the 2nd quarter worth $105,000. Finally, HighTower Advisors LLC grew its position in Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 4,000 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Trading Down 10.6 %

Shares of OMER opened at $8.84 on Friday. The company has a market capitalization of $512.28 million, a price-to-earnings ratio of -3.83 and a beta of 2.01. The stock has a 50 day moving average of $8.89 and a 200 day moving average of $5.84. Omeros Co. has a 12 month low of $2.61 and a 12 month high of $13.60.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on OMER. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Finally, D. Boral Capital initiated coverage on Omeros in a research note on Monday, December 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.